Pro-Dex (NASDAQ:PDEX - Get Free Report) is projected to announce its earnings results before the market opens on Thursday, February 13th. Analysts expect the company to announce earnings of $0.38 per share and revenue of $13.80 million for the quarter.
Pro-Dex (NASDAQ:PDEX - Get Free Report) last issued its quarterly earnings data on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.38 by $0.23. Pro-Dex had a return on equity of 21.68% and a net margin of 11.06%. On average, analysts expect Pro-Dex to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Shares of Pro-Dex stock opened at $32.47 on Thursday. The stock has a market capitalization of $105.85 million, a P/E ratio of 16.15 and a beta of 0.53. Pro-Dex has a 12-month low of $16.18 and a 12-month high of $59.60. The company has a quick ratio of 1.44, a current ratio of 2.58 and a debt-to-equity ratio of 0.33. The company has a 50-day simple moving average of $46.84 and a 200 day simple moving average of $34.96.
PDEX has been the topic of a number of research reports. StockNews.com cut shares of Pro-Dex from a "strong-buy" rating to a "buy" rating in a research note on Monday. Ascendiant Capital Markets increased their price objective on Pro-Dex from $30.00 to $52.00 and gave the company a "buy" rating in a research report on Monday, November 11th.
Read Our Latest Analysis on PDEX
In other news, Director Raymond E. Cabillot sold 6,931 shares of the business's stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $45.22, for a total value of $313,419.82. Following the sale, the director now directly owns 337,752 shares in the company, valued at $15,273,145.44. The trade was a 2.01 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders sold a total of 27,770 shares of company stock worth $1,239,312 in the last quarter. Corporate insiders own 47.50% of the company's stock.
Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pro-Dex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pro-Dex wasn't on the list.
While Pro-Dex currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.